{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:33:57Z","timestamp":1793658837784,"version":"4.5.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clml.2023.12.006","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T03:03:46Z","timestamp":1702177426000},"page":"254-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-9613","authenticated-orcid":false,"given":"Alexandra","family":"Rezazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Pruett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Detzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Edwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.12.006_bib0001","unstructured":"Lynch DT, Koya S, Acharya U, Kumar A. Mantle Cell Lymphoma. In: StatPearls. Treasure Island, FL 2022."},{"issue":"6","key":"10.1016\/j.clml.2023.12.006_bib0002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.clml.2023.12.006_bib0003","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.12.006_bib0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.clml.2017.05.005","article-title":"Effect of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma after autologous hematopoietic cell transplantation","volume":"17","author":"Kapke","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.12.006_bib0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clml.2013.08.009","article-title":"Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission","volume":"14","author":"Truong","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2023.12.006_bib0006","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/1042819021000040323","article-title":"The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma","volume":"44","author":"Guppy","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.12.006_bib0007","unstructured":"Network NCC. B cell lymphomas (Version 5.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"4","key":"10.1016\/j.clml.2023.12.006_bib0008","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/10428194.2017.1361032","article-title":"Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility","volume":"59","author":"Guidot","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2023.12.006_bib0009","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ijc.29433","article-title":"Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study","volume":"137","author":"Chien","year":"2015","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.clml.2023.12.006_bib0010","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.clml.2023.12.006_bib0011","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.hoc.2020.06.006","article-title":"Minimal residual disease in mantle cell lymphoma: Methods and clinical significance","volume":"34","author":"Ladetto","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.clml.2023.12.006_bib0012","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblast lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2023.12.006_bib0013","unstructured":"clonoSEQ. Technical summary. Seattle WABhwcct-s. In. https:\/\/www.clonoseq.com\/wp-content\/uploads\/2021\/08\/PNL-10027-03_clonoSEQ-Technical-Information.pdf."},{"issue":"26","key":"10.1016\/j.clml.2023.12.006_bib0014","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.12.006_bib0015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.12.006_bib0016","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2022-167936","article-title":"MRD-negativity as a potential surrogate endpoint after frontline DLBCL therapy: Pooled analysis of trials & implications for clinical trial design","volume":"140","author":"Roschewski","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2023.12.006_bib0017","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1182\/blood.V122.21.1767.1767","article-title":"DNA sequencing-based monitoring of serum predicts clinical relapse before CT imaging in diffuse large B-cell lymphoma","volume":"122","author":"Roschewski","year":"2013","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.12.006_bib0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2021-150572","article-title":"A prospective multicenter study of minimal residual disease assessment using a next-generation immunosequencing assay and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.12.006_bib0019","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.12.006_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136565","article-title":"Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study","volume":"136","author":"Epstein-Peterson","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.12.006_bib0021","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"issue":"27","key":"10.1016\/j.clml.2023.12.006_bib0022","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: Results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.12.006_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-140965","article-title":"Prognostic value of circulating tumor DNA (ctDNA) in autologous stem cell graft and post-transplant plasma samples among patients with diffuse large B-cell lymphoma","volume":"136","author":"Merryman","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2023.12.006_bib0024","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502302195X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502302195X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T02:13:45Z","timestamp":1712542425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502302195X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S215226502302195X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}